Business Wire

Hotwire Global Communications Expands Its Global Tech Communications Leadership With New Hires and Client Wins

30.9.2021 16:00:00 EEST | Business Wire | Press release

Share

Hotwire, the global tech communications consultancy, is welcoming new leaders as the company continues further expansion of its capabilities and adds new, innovative brands to the client roster.

Hotwire is building on its strategic acquisition of McDonald Butler Associates to unlock new possibilities of growth and present clients with a more robust communications offering and access to new skills and services. This new level of communication has been designed to build brand reputation, strengthen stakeholder relationships and deliver revenue growth, igniting the entire marketing ecosystem and supporting CMOs in growing their businesses.

“Technology and innovation leaders are continuing to manage complexity and are seeking out solutions to support,” said Heather Kernahan, global CEO of Hotwire. “This year we took steps to narrow the gaps that exist between marketing and sales with new integrated offerings and strengthened our relationships with clients as they navigated major shifts in their business. We’re also working with some amazing new brands and deepening our expertise and leadership across key areas of the business.”

New Leaders Support Rapid Growth

Hotwire continues to add senior leaders in strategy, planning, digital and client consulting to its teams across the world. This past quarter key hires have been made in Germany, the U.K., and the U.S.

In Germany, Martin Opercan joined Hotwire as a Senior Director, Strategic Growth and will be responsible for client strategy and planning. Martin brings over 20 years of experience in marketing, communications and business development and most recently oversaw the Munich office for diffferent.

Rebecca Rhodes and Anastasia Pavolva recently joined the Hotwire U.K. team. Rebecca is Head of Planning and before joining Hotwire, ran her own consultancy, SuperHuman and also previously was Global Chief Creative Officer at Golin. Anastasia is a Strategy Director with experience working in global agencies such as Ogilvy and in brand management at Procter & Gamble.

In the U.S., two new Senior Vice Presidents will join the leadership and client services team. Andrea Holland has worked in tech comms across large global brands including Intuit, PayPal and LegalZoom as well as early stage B2C tech startups. Andrea is a PR instructor and author for LinkedIn Learning and most recently ran her own consultancy, DialedPR. She also founded the nation's #1 jobs site for PR professionals looking for remote work, RemotePRJobs. Jessica Heagerty comes to Hotwire from Dell Technologies where she held roles in Analyst Relations and Field Marketing. Jessica started her career working for global brands in leading communications agencies.

Tech Innovators Choose Hotwire to Ignite New Opportunities

As Hotwire continues to provide a new level of communication expertise helping companies build brand reputation, strengthen stakeholder relationships and deliver revenue growth, it’s igniting the entire marketing ecosystem and supporting ambitious companies in growing their businesses.

New clients include fast growing and global innovators who selected Hotwire for its technology and innovation expertise and consultancy approach. Most recently, Hotwire signed on Aircall, BAM Karaoke, Bright Machines, Cobrainer, QA, Rocket App and Splashtop.

Award Winning Client Work and Global Recognition

Hotwire and individuals across the agency continue to gain recognition for leadership and impactful client work. Ludi Garcia, Managing Director of Hotwire Spain, was recently recognized as the #1 most admired communications professional in Spain by SCOPEN and Hotwire was named Best Comms PR consultancy, as voted for by PR professionals working in agencies.

Hotwire’s work on Zoomtopia, Zoom’s annual conference, received Honorable Mention for Ragan Comms' Media Relations Award for Virtual Event and is shortlisted in the PR report awards.

The company was also recently named in the Propel 100 list as one of the most influential PR agencies in the world in 2021.

Expanding Partnerships in The Tech Ecosystem

Hotwire is partnering with organizations across the world who are working to advance technology innovation and the leaders pushing the industry forward. The company is now a member of Tech UK, which brings together people, companies and organizations to realize the positive outcomes of what digital technology can achieve.

Hotwire is also a sponsor for Get On Board, which is a week of education and training to prepare women leaders for Board positions. The company is also a sponsor of Alley to the Valley, a community of accomplished women who fast-track business opportunities for each other. Hotwire supports board readiness and women in leadership with Executive Thought Leadership and Media Training and Speaker Readiness services.

To learn more about Hotwire, visit https://www.hotwireglobal.com/.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Hotwire
Kelsey Quickstad
kelsey.quickstad@hotwireglobal.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye